A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

← catalyst calendar

NCT04227847 · readout in 319 d

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

178estimated

Sites

Countries

Japan, Netherlands, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-08-07

actual

When the study began enrolling

Primary completion

2027-07-04

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-07-03

estimated

The whole study's end, after follow-up

First posted

2020-01-14

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions

Drug: SEA-CD70
Drug: azacitidine — also filed as VIDAZA
Drug: Venetoclax — also filed as Venclexta

Primary outcomes

what the primary-completion date above is the date OF

Number of participants with adverse events (AEs)

measured Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years

Number of participants with laboratory abnormalities

measured Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years

Number of participants with a dose-limiting toxicity (DLT) at each dose level (Parts A and D only)

measured Though end of DLT evaluation period; up to approximately 4 weeks

Publications

PMID 37093350 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed